Cingulate INC 8-K filings

NASDAQ

26 Feb 2024

CING

8-K: Cingulate Inc. Granted Nasdaq Extension, Regains Board Compliance

Cingulate Inc. has been granted an extension to maintain its Nasdaq listing through May 13, 2024, after regaining compliance with board composition requirements.

NASDAQ

13 Feb 2024

CING

Cingulate INC

8-K: Cingulate Inc. Appoints Three New Directors Following Successful Capital Raise

Cingulate Inc. has appointed three new independent directors to its board, following a recent public offering and other capital raising activities.

NASDAQ

6 Feb 2024

CING

Cingulate INC

8-K: Cingulate Inc. Secures $7.5 Million in Public Offering to Advance Drug Pipeline

Cingulate Inc. has successfully priced and closed a public offering, raising $7.5 million to support the development and commercialization of its pharmaceutical products.

NASDAQ

29 Jan 2024

CING

Cingulate INC

8-K: Cingulate Inc. Converts $3.3 Million Debt to Equity, Appoints New CFO

Cingulate Inc. has converted $3.3 million of debt and accrued interest into equity and appointed Jennifer Callahan as its new Chief Financial Officer.